{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:13:06Z","timestamp":1790777586848,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s00115-004-1830-4","type":"journal-article","created":{"date-parts":[[2004,12,8]],"date-time":"2004-12-08T08:56:55Z","timestamp":1102496215000},"page":"681-689","source":"Crossref","is-referenced-by-count":6,"title":["Apomorphin bei der Behandlung des Morbus Parkinson"],"prefix":"10.1007","volume":"76","author":[{"given":"D.","family":"Dressler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"1830_CR1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1365-2133.1998.02128.x","volume":"138","author":"Acland","year":"1998","unstructured":"Acland KM, Churchyard A, Fletcher CL et al. (1998) Panniculitis in association with apomorphine infusion. Br J Dermatol 138:480\u2013482","journal-title":"Br J Dermatol"},{"key":"1830_CR2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/mds.870080207","volume":"8","author":"Bonuccelli","year":"1993","unstructured":"Bonuccelli U, Piccini P, Del Dotto P et al. (1993) Apomorphine test for dopaminergic responsiveness: a dose assessment study. Mov Disord 8:158\u2013164","journal-title":"Mov Disord"},{"key":"1830_CR3","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(88)90860-4","volume":"2","author":"Chaudhuri","year":"1988","unstructured":"Chaudhuri KR, Critchley P, Abbott RJ et al. (1988) Subcutaneous apomorphine for on-off oscillations in Parkinson\u2019s disease. Lancet 2 (8622):1260","journal-title":"Lancet"},{"key":"1830_CR4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jnnp.69.5.590","volume":"69","author":"Clarke","year":"2000","unstructured":"Clarke CE, Davies P (2000) Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 69:590\u2013594","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1830_CR5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jnnp.64.5.573","volume":"64","author":"Colzi","year":"1998","unstructured":"Colzi A, Turner K, Lees AJ (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 64:573\u2013576","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1830_CR6","first-page":"1309","volume":"20","author":"Corsini","year":"1981","unstructured":"Corsini GU, Pitzalis GF, Bernardi F et al. (1981) The use of dopamine agonists in the treatment of schizophrenia. Neuropharmacology 20:1309\u20131313","journal-title":"Neuropharmacology"},{"key":"1830_CR7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp.54.10.870","volume":"54","author":"D\u2019Costa","year":"1991","unstructured":"D\u2019Costa DF, Abbott RJ, Pye IF et al. (1991) The apomorphine test in parkinsonian syndromes. J Neurol Neurosurg Psychiatry 54:870\u2013872","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1830_CR8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00002826-199619030-00001","volume":"19","author":"Dewey","year":"1996","unstructured":"Dewey RB Jr, Maraganore DM, Ahlskog JE et al. (1996) Intranasal apomorphine rescue therapy for parkinsonian \u201coff\u201d periods. Clin Neuropharmacol 19:193\u2013201","journal-title":"Clin Neuropharmacol"},{"key":"1830_CR9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"Dewey","year":"2001","unstructured":"Dewey RB Jr, Hutton JT, LeWitt PA et al. (2001) A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58:1385\u20131392","journal-title":"Arch Neurol"},{"key":"1830_CR10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1054-3589(08)60482-2","volume":"15","author":"Di Chiara","year":"1978","unstructured":"Di Chiara G, Gessa GL (1978) Pharmacology and neurochemistry of apomorphine. Adv Pharmacol Chemother 15:87\u2013160","journal-title":"Adv Pharmacol Chemother"},{"key":"1830_CR11","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1464-410X.2004.04816.x","volume":"93","author":"Eardley","year":"2004","unstructured":"Eardley I, Wright P, MacDonagh R et al. (2004) An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 93:1271\u20131275","journal-title":"BJU Int"},{"key":"1830_CR12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1353-8020(97)00009-6","volume":"3","author":"Ellis","year":"1997","unstructured":"Ellis C, Lemmens G, Parkes JD et al. (1997) Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord 3:103\u2013107","journal-title":"Parkinsonism Relat Disord"},{"key":"1830_CR13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00002826-199706000-00009","volume":"20","author":"Esteban","year":"1997","unstructured":"Esteban Munoz J, Marti MJ, Marin C et al. (1997) Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations. Clin Neuropharmacol 20:245\u2013252","journal-title":"Clin Neuropharmacol"},{"key":"1830_CR14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1017\/S0317167100038518","volume":"23","author":"Galvez-Jimenez","year":"1996","unstructured":"Galvez-Jimenez N, Lang AE (1996) Perioperative problems in Parkinson\u2019s disease and their management: apomorphine with rectal domperidone. Can J Neurol Sci 23:198\u2013203","journal-title":"Can J Neurol Sci"},{"key":"1830_CR15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ana.410260209","volume":"26","author":"Gancher","year":"1989","unstructured":"Gancher ST, Woodward WR, Boucher B et al. (1989) Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 26:232\u2013238","journal-title":"Ann Neurol"},{"key":"1830_CR16","first-page":"163","volume":"66","author":"Gancher","year":"1989","unstructured":"Gancher ST, Bennett W, English J (1989) Studies of renal function in animals chronically treated with apomorphine. Res Commun Chem Pathol Pharmacol 66:163\u2013166","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"1830_CR17","first-page":"137","volume":"45","author":"Gancher","year":"1995","unstructured":"Gancher S (1995) Pharmacokinetics of apomorphine in Parkinson\u2019s disease. J Neural Transm Suppl 45:137\u2013141","journal-title":"J Neural Transm Suppl"},{"key":"1830_CR18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/mds.870100108","volume":"10","author":"Gancher","year":"1995","unstructured":"Gancher ST, Nutt JG, Woodward WR (1995) Apomorphine infusional therapy in Parkinson\u2019s disease: clinical utility and lack of tolerance. Mov Disord 10:37\u201343","journal-title":"Mov Disord"},{"key":"1830_CR19","first-page":"297","volume":"80","author":"Gassen","year":"1999","unstructured":"Gassen M, Gross A, Youdim MB (1999) Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties. Adv Neurol 80:297\u2013302","journal-title":"Adv Neurol"},{"key":"1830_CR20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/1531-8257(199907)14:4<612::AID-MDS1010>3.0.CO;2-6","volume":"14","author":"Grunblatt","year":"1999","unstructured":"Grunblatt E, Mandel S, Berkuzki T et al. (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 14:612\u2013618","journal-title":"Mov Disord"},{"key":"1830_CR21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01376517-200102000-00004","volume":"33","author":"Hagell","year":"2001","unstructured":"Hagell P, Odin P (2001) Apomorphine in the treatment of Parkinson\u2019s disease. J Neurosci Nurs 33:21\u201338","journal-title":"J Neurosci Nurs"},{"key":"1830_CR22","first-page":"245","volume":"28","author":"Helmers","year":"1977","unstructured":"Helmers JH (1977) Preliminary report of domperidone (R 33182), a new antiemetic compound. A pilot study. Acta Anaesthesiol Belg 28:245\u2013250","journal-title":"Acta Anaesthesiol Belg"},{"key":"1830_CR23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0140-6736(90)91531-E","volume":"336","author":"Hughes","year":"1990","unstructured":"Hughes AJ, Lees AJ, Stern GM (1990) Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 336 (8706):32\u201334","journal-title":"Lancet"},{"key":"1830_CR24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/mds.870080208","volume":"8","author":"Hughes","year":"1993","unstructured":"Hughes AJ, Bishop S, Kleedorfer B et al. (1993) Subcutaneous apomorphine in Parkinson\u2019s disease: response to chronic administration for up to five years. Mov Disord 8:165\u2013170","journal-title":"Mov Disord"},{"key":"1830_CR25","doi-asserted-by":"crossref","unstructured":"Jenner P (2003) Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson\u2019s disease. Curr Opin Neurol 16 [Suppl\u00a01]:S3\u20137","DOI":"10.1097\/00019052-200312001-00002"},{"key":"1830_CR26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/mds.1276","volume":"17","author":"Kanovsky","year":"2002","unstructured":"Kanovsky P, Kubova D, Bares M et al. (2002) Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 17:188\u2013191","journal-title":"Mov Disord"},{"key":"1830_CR27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1445-5994.1991.tb04696.x","volume":"21","author":"Kempster","year":"1991","unstructured":"Kempster PA, Iansek R, Larmour I (1991) Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations. Aust N Z J Med 21:314\u2013318","journal-title":"Aust N Z J Med"},{"key":"1830_CR28","first-page":"221","volume":"64","author":"Kreczy-Kleedorfer","year":"1993","unstructured":"Kreczy-Kleedorfer B, Wagner M, Bosch S et al. (1993) Langzeitergebnisse kontinuierlicher subkutaner Apomorphinpumpentherapie bei Patienten mit fortgeschrittener Parkinson-Krankheit. Nervenarzt 64:221\u2013225","journal-title":"Nervenarzt"},{"key":"1830_CR29","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/jnnp.52.12.1440","volume":"52","author":"Lees","year":"1989","unstructured":"Lees AJ, Montastruc JL, Turjanski N et al. (1989) Sublingual apomorphine and Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 52:1440","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1830_CR30","unstructured":"Lees AJ, Richardson C, Turner K (1998) Treatment of Parkinson\u2019s disease with apomorphine, Shared Guidelines, 3rd edn. UCL Hospitals NHS Trust"},{"key":"1830_CR31","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","volume":"17","author":"Manson","year":"2002","unstructured":"Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson\u2019s disease: long-term follow-up study of 64 patients. Mov Disord 17:1235\u20131241","journal-title":"Mov Disord"},{"key":"1830_CR32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1098\/rspl.1868.0094","volume":"17","author":"Matthiessen","year":"1869","unstructured":"Matthiessen A, Wright CRA (1869) Researches into the chemical constitution of the opium bases Part I: on the action of hydrochloric acid on morhia. Proc R Soc Lond B Biol Sci 17:455\u2013460","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"1830_CR33","unstructured":"Merello M, Leiguarda R (1995) Tratamiento de las fluctuationes motoras de la enfermedad de parkinson con inyecciones subcutaneas de apomorfina. Medicina (B Aires) 55:5\u201310"},{"key":"1830_CR34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002826-199704000-00008","volume":"20","author":"Merello","year":"1997","unstructured":"Merello M, Pikielny R, Cammarota A et al. (1997) Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson\u2019s disease patients: a double-blind single-dose study. Clin Neuropharmacol 20:165\u2013167","journal-title":"Clin Neuropharmacol"},{"key":"1830_CR35","unstructured":"Merello M, Piran Arce G, Nouzeilles M et al. (2000) Antidyskinetic effect of long-term waking day continuous infusion of apomorphine compared to posteroventral pallidotomy. Mov Disord 15 [Suppl\u00a03]:54"},{"key":"1830_CR36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00702-003-0815-y","volume":"110","author":"Muller","year":"2003","unstructured":"Muller T, Benz S, Bornke C et al. (2003) Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson\u2019s disease. J Neural Transm 110:603\u2013609","journal-title":"J Neural Transm"},{"key":"1830_CR37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jnnp.58.6.681","volume":"58","author":"Ostergaard","year":"1995","unstructured":"Ostergaard L, Werdelin L, Odin P et al. (1995) Pen injected apomorphine against off phenomena in late Parkinson\u2019s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 58:681\u2013687","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1830_CR38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/jnnp.65.5.709","volume":"65","author":"Pietz","year":"1998","unstructured":"Pietz K, Hagell P, Odin P (1998) Subcutaneous apomorphine in late stage Parkinson\u2019s disease: a long term follow up. J Neurol Neurosurg Psychiatry 65:709\u2013716","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1830_CR39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1398-9995.1979.tb01370.x","volume":"34","author":"Podolec","year":"1979","unstructured":"Podolec Z, Vetulani J, Bednarczyk B et al. (1979) Central dopamine receptors regulate blood eosinophilia in the rat. Allergy 34:103\u2013110","journal-title":"Allergy"},{"key":"1830_CR40","first-page":"73","volume":"16","author":"Poewe","year":"1989","unstructured":"Poewe W, Kleedorfer B, Gerstenbrand F et al. (1989) Die Behandlung von Parkinsonpatienten mit L-Dopa-Wirkungsfluktuation mittels subkutanen Apomorphingaben. Acta Neurol 16:73\u201377","journal-title":"Acta Neurol"},{"key":"1830_CR41","first-page":"116","volume":"146","author":"Pollak","year":"1990","unstructured":"Pollak P, Champay AS, Gaio JM et al. (1990) Administration sous-cutanee d\u2019apomorphine dans les fuctuations motrices de la maladie de Parkinson. Rev Neurol (Paris) 146:116\u2013122","journal-title":"Rev Neurol (Paris)"},{"key":"1830_CR42","doi-asserted-by":"crossref","unstructured":"Priano L, Albani G, Calderoni S et al. (2002). Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson\u2019s disease. Neurol Sci 23 [Suppl\u00a02]:S99\u2013100","DOI":"10.1007\/s100720200088"},{"key":"1830_CR43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/mds.870100107","volume":"10","author":"Przedborski","year":"1995","unstructured":"Przedborski S, Levivier M, Raftopoulos C et al. (1995) Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord 10:28\u201336","journal-title":"Mov Disord"},{"key":"1830_CR44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/jnnp.57.5.562","volume":"57","author":"Rodriguez","year":"1994","unstructured":"Rodriguez M, Lera G, Vaamonde J et al. (1994) Motor response to apomorphine and levodopa in asymmetric Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 57:562\u2013566","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1830_CR45","first-page":"251","volume":"76","author":"Schwab","year":"1951","unstructured":"Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson\u2019s disease. Trans Am Neurol Assoc 76:251\u2013253","journal-title":"Trans Am Neurol Assoc"},{"key":"1830_CR46","first-page":"653","volume":"60","author":"Stocchi","year":"1993","unstructured":"Stocchi F, Bramante L, Monge A et al. (1993) Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol 60:653\u2013655","journal-title":"Adv Neurol"},{"key":"1830_CR47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8257(199903)14:2<358::AID-MDS1025>3.0.CO;2-Q","volume":"14","author":"Stocchi","year":"1999","unstructured":"Stocchi F, Farina C, Nordera G et al. (1999) Implantable venous access system for apomorphine infusion in complicated Parkinson\u2019s disease. Mov Disord 14:358","journal-title":"Mov Disord"},{"key":"1830_CR48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0303-8467(93)90128-4","volume":"95","author":"van Laar","year":"1993","unstructured":"van Laar T, Jansen EN, Essink AW et al. (1993) A double-blind study of the efficacy of apomorphine and its assessment in \u2018off\u2019-periods in Parkinson\u2019s disease. Clin Neurol Neurosurg 95:231\u2013235","journal-title":"Clin Neurol Neurosurg"},{"key":"1830_CR49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.870100405","volume":"10","author":"van Laar","year":"1995","unstructured":"van Laar T, Jansen EN, Neef C et al. (1995) Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson\u2019s disease: a study of five different suppositories. Mov Disord 10:433\u2013439","journal-title":"Mov Disord"},{"key":"1830_CR50","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/mds.1133","volume":"16","author":"Wang","year":"2001","unstructured":"Wang HC, Hsieh Y (2001) Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. Mov Disord 16:765\u2013767","journal-title":"Mov Disord"},{"key":"1830_CR51","first-page":"411","volume":"48","author":"Weil","year":"1884","unstructured":"Weil E (1884) De L\u2019apomorphine dans certain troubles nerveaux. Lyon Med 48:411\u2013419","journal-title":"Lyon Med"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-004-1830-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-004-1830-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-004-1830-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:00:44Z","timestamp":1558587644000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-004-1830-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s00115-004-1830-4","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}